- Home
- NODK vs PRQR Comparison
NODK vs PRQR Comparison
Compare NODK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- PRQR
- Stock Information
- Founded
- NODK 1946
- PRQR 2012
- Country
- NODK United States
- PRQR Netherlands
- Employees
- NODK N/A
- PRQR N/A
- Industry
- NODK Property-Casualty Insurers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- PRQR Health Care
- Exchange
- NODK Nasdaq
- PRQR Nasdaq
- Market Cap
- NODK 289.0M
- PRQR 250.7M
- IPO Year
- NODK 2017
- PRQR 2014
- Fundamental
- Price
- NODK $13.49
- PRQR $2.15
- Analyst Decision
- NODK
- PRQR Strong Buy
- Analyst Count
- NODK 0
- PRQR 7
- Target Price
- NODK N/A
- PRQR $8.14
- AVG Volume (30 Days)
- NODK 10.9K
- PRQR 338.6K
- Earning Date
- NODK 11-07-2025
- PRQR 11-06-2025
- Dividend Yield
- NODK N/A
- PRQR N/A
- EPS Growth
- NODK N/A
- PRQR N/A
- EPS
- NODK 0.11
- PRQR N/A
- Revenue
- NODK $297,973,000.00
- PRQR $18,859,556.00
- Revenue This Year
- NODK N/A
- PRQR N/A
- Revenue Next Year
- NODK N/A
- PRQR N/A
- P/E Ratio
- NODK $122.21
- PRQR N/A
- Revenue Growth
- NODK N/A
- PRQR N/A
- 52 Week Low
- NODK $12.01
- PRQR $1.07
- 52 Week High
- NODK $17.24
- PRQR $3.97
- Technical
- Relative Strength Index (RSI)
- NODK 53.84
- PRQR 42.60
- Support Level
- NODK $13.30
- PRQR $1.97
- Resistance Level
- NODK $13.70
- PRQR $2.30
- Average True Range (ATR)
- NODK 0.22
- PRQR 0.17
- MACD
- NODK 0.02
- PRQR -0.01
- Stochastic Oscillator
- NODK 66.03
- PRQR 48.05
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.